Abbvie (ABBV) news
Recent news
Priced: LBBW EUR 750M 2Y covered MS+7
AInvest Wire · 18h agoAbbVie Inc.: UBS raises target price to $275 from $260
AInvest Wire · 3d agoArgenx SE shares up 4.7%
Argenx SE (NASDAQ: ARGX) shares rose 4.7% on October 9, 2026, following continued momentum in the biotechnology sector and positive investor sentiment surrounding the company’s commercial performance. The stock is currently trading at $818.63, with a 52-week range of $661.85 to $1,072.75. The…
AInvest Wire · 4d agoIambic Therapeutics - Ark investment and Duquesne family office indicate interest to purchase up to $60 mln in shares in IPO at IPO price
San Diego-based Iambic Therapeutics, a clinical-stage biotech firm leveraging AI for drug discovery, has filed for a $100 million IPO on the Nasdaq under the ticker "IAM". The company, backed by investors including Nvidia and the Qatar Investment Authority, is developing proprietary AI models with…
AInvest Wire · 4d agoAbbVie's telisotuzumab adizutecan (temab-A) receives two breakthrough therapy designations from the U.S. FDA for CRC and NSCLC
AbbVie Inc. (ABBV) has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA) for its investigational antibody-drug conjugate (ADC), telisotuzumab adizutecan (ABBV-400, temab-A). The designations are for refractory metastatic colorectal cancer and advanced…
AInvest Wire · 5d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.